AMOXICILLIN AND CLAVULANATE POTASSIUM

Post-LOE

amoxicillin and clavulanate potassium

Deva Holdings
ANDAORALFOR SUSPENSION
Approved
Sep 2023
Lifecycle
Post-LOE
Competitive Pressure
30/100

Mechanism of Action

[see Microbiology ( )].

Indications (7)

equal to 40 kg with: Recurrentpersistent acute otitis media due to Sacute otitis media due to Sdevelopment of drug-resistant bacteriamaintain the effectiveness of Amoxicillinclavulanate potassium for oral suspension600 mg/42
Company
DH
Deva Holdings
Turkey - Istanbul
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers